Viva Biotech Holdings (FRA:VB0) Total Stockholders Equity: €484.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VB0 Viva Biotech Holdings FRA:VB0
43 GF Score
Price €0.14
GF Value €0.08
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings Total Stockholders Equity?

Viva Biotech Holdings FRA:VB0 +2.96% 43 Total Stockholders Equity is €484.6 Mil as of Dec. 2025. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Viva Biotech Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €484.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Viva Biotech Holdings's Book Value per Share for the quarter that ended in Dec. 2025 was €0.23. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Viva Biotech Holdings's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.33.

Viva Biotech Holdings  (FRA:VB0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Viva Biotech Holdings's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(484.592-0)/2111.098
=0.23

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Viva Biotech Holdings's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(117.898 + 43.437) / 484.592
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Total Stockholders Equity Related Terms

Viva Biotech Holdings Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Total Stockholders Equity Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 543.75 488.10 473.63 498.75 484.59

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 473.63 485.16 498.75 470.04 484.59
FRA:VB0
43GF Score
Viva Biotech Holdings FRA:VB0
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €484.6 Mil mean?
Viva Biotech Holdings (FRA:VB0) has a Total Stockholders Equity of €484.6 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Viva Biotech Holdings and its competitors.
Is Viva Biotech Holdings' Total Stockholders Equity too high?
Viva Biotech Holdings' current Total Stockholders Equity is €484.6 Mil. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Total Stockholders Equity compare to VRTX and REGN?
Viva Biotech Holdings' Total Stockholders Equity of €484.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Total Stockholders Equity is €484.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.14 — trading 73.8% above its estimated fair value. The current Total Stockholders Equity is €484.6 Mil. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Total Stockholders Equity is €484.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.14 is trading 73.8% above its estimated GF Value™ of €0.08. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

  • Total Stockholders Equity: €484.6 Mil
  • GF Value™: €0.08 vs. price of €0.14 (73.8% above fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USA01873:Hong Kong
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score

Get the complete analysis for FRA:VB0

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.08
GF Value